Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $17 from $19 and keeps an Overweight rating on the shares. The firm says there wasn’t much new in the company’s update, but there was more clarity on upcoming catalysts for belrestotug and it thinks EOS-984 data expected in second half of 2025 could be interesting for the company beyond TIGIT.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics
- iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position
- iTeos Therapeutics reports Q4 EPS ($1.01), consensus ($1.02)
- iTeos Therapeutics Plans 2025 Data Presentation on Therapies
- iTeos Therapeutics outlines business updates, strategies for 2025